IDRI (Infectious Disease Research Institute)
The Access to Advanced Health Institute (AAHI) is a nonprofit biotech research institute dedicated to developing affordable, effective, and accessible vaccine technologies to address global health inequalities. With nearly three decades of innovation, AAHI focuses on translating high-impact science into scalable, field-ready solutions that save lives in underserved communities worldwide. Their mission emphasizes health equity through innovation, creating systems that make health solutions deployable at scale, especially in low-resource settings. They develop vaccines for diseases such as tuberculosis, malaria, HIV, leishmaniasis, and others, with a focus on temperature stability, adjuvant enhancement, and innovative delivery platforms. AAHI collaborates globally with partners, governments, and communities to ensure their technologies reach those in need, aiming to reshape health equity and combat infectious diseases, cancers, autoimmune diseases, and more.
Industries
Nr. of Employees
medium (51-250)
IDRI (Infectious Disease Research Institute)
Products
Temperature-stable tuberculosis vaccine candidate
A next-generation, adjuvant-formulated tuberculosis vaccine candidate developed for thermal stability to facilitate distribution and use in low-resource settings.
Spray-dried vaccine platform
Platform technology converting liquid vaccine formulations into dry, room-temperature-stable powders for improved distribution and needle-free delivery options.
Temperature-stable tuberculosis vaccine candidate
A next-generation, adjuvant-formulated tuberculosis vaccine candidate developed for thermal stability to facilitate distribution and use in low-resource settings.
Spray-dried vaccine platform
Platform technology converting liquid vaccine formulations into dry, room-temperature-stable powders for improved distribution and needle-free delivery options.
Services
Formulation development and customization
Custom formulation of adjuvants and vaccine antigens, including evaluation and optimization for stability, delivery route, and immune biasing.
Preclinical evaluation and research material supply
Provision of research materials and conduct of preclinical studies to assess immunogenicity and safety of antigen–adjuvant combinations.
Compatibility studies and in vitro bioactivity testing
Assays to test mixing compatibility of adjuvants with chosen antigens and in vitro assays to measure innate immune stimulation on human cells.
Clinical and regulatory consulting
Support for clinical trial design and coordination, and assistance with preparation of regulatory applications for clinical progression.
Partnerships for manufacturing scale-up
Collaboration with contract development and manufacturing organizations and local partners to scale production and enable program deployment in target regions.
Formulation development and customization
Custom formulation of adjuvants and vaccine antigens, including evaluation and optimization for stability, delivery route, and immune biasing.
Preclinical evaluation and research material supply
Provision of research materials and conduct of preclinical studies to assess immunogenicity and safety of antigen–adjuvant combinations.
Compatibility studies and in vitro bioactivity testing
Assays to test mixing compatibility of adjuvants with chosen antigens and in vitro assays to measure innate immune stimulation on human cells.
Clinical and regulatory consulting
Support for clinical trial design and coordination, and assistance with preparation of regulatory applications for clinical progression.
Partnerships for manufacturing scale-up
Collaboration with contract development and manufacturing organizations and local partners to scale production and enable program deployment in target regions.
Expertise Areas
- Vaccine adjuvant development
- Thermostable vaccine formulation
- Mucosal and needle-free vaccine delivery
- Preclinical immunogenicity and compatibility testing
Key Technologies
- Spray-drying for vaccine stabilization
- Lyophilization (freeze-drying)
- Liposomal formulation
- Squalene emulsion systems